Wells Fargo Maintains Equal-Weight on Intellia Therapeutics, Raises Price Target to $15

Intellia Therapeutics, Inc. +1.08% Pre

Intellia Therapeutics, Inc.

NTLA

14.94

14.91

+1.08%

-0.20% Pre
Wells Fargo analyst Yanan Zhu maintains Intellia Therapeutics (NASDAQ: NTLA) with a Equal-Weight and raises the price target from $12 to $15.